Accessibility StatementSkip Navigation WASHINGTON, Oct. 29, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2025. GAAP Financial Results Net loss was $22.6 million in the third quarter of 2025 compared to net loss of$5.3 million in the third quarter of 2024. Diluted net loss per share was $0.38 in the third quarter of 2025 compared to diluted net loss per share of$0.09 in the third quarter o ...